The Research On Hyperparathyroidism Increase The Risk Of Cardiovascular Disease In Chronic Kidney Disease

Secondary hyperparathyroidism (SHPT) is one of the earlycomplication in chronic kidney disease(CKD). When parathyroid hormone(PTH) in serum more than physiological concentrations in patients withCKD,it may promote myocardial, valvular and vascular calcification,aggravate cardiac hypertrophy, lead to arrhythmias and cardiac-dysfunction, and what’s more, even affect blood lipids and blood pressure.it is an important factor that leads to the increase of incidence ofcardiovascular events and related mortality. Currently, the treatments ofSHPT mainly include diet control, phosphorus chelating agents, vitamin Dand its derivatives, surgery and so on. In addition, Velcalcetide (AMG416),a novel peptide agonist of the calcium sensing receptor (CaSR), has broadapplication prospects of new drugs in the effective treatment of secondaryhyperparathyroidism.